Israeli Company Galmed Gets Positive Trial Results for Liver Drug Israeli Company Galmed Gets Positive Trial Results for Liver Drug
Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for non-alcoholic steatohepatitis (NASH), a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.Reuters Health Information
In conclusion, postnatal high-fat diet aggravated the prenatal dexamethasone-induced liver steatosis in adult rat offspring via inflammation, oxidative stress and cellular apoptosis, which may be ameliorated by prenatal melatonin therapy. PMID: 30112044 [PubMed]
ConclusionsNAFLD could be dealt with laparoscopic sleeve gastrectomy, preventing its progression into cirrhosis. SG can be performed in patients with obesity and metabolic syndrome, with NAFLD showing satisfactory results 12 months after surgery. NAFLD should be a formal indication for bariatric surgery.
AbstractPurpose of ReviewThe global prevalence of type 2 diabetes (T2D) is escalating at alarming rates, demanding the development of additional classes of therapeutics to further reduce the burden of disease. Recent studies have indicated that increasing the metabolic activity of brown and beige adipose tissue may represent a novel means to reduce circulating glucose and lipids in people with T2D. The AMP-activated protein kinase (AMPK) is a cellular energy sensor that has recently been demonstrated to be important in potentially regulating the metabolic activity of brown and beige adipose tissue. The goal of this review ...
Non-alcoholic fatty liver disease (NAFLD), with its increasing prevalence and association with various co-morbidities, such as diabetes, cardiovascular disease and metabolic syndrome, is a growing concern. Previously thought to predominantly affect obese individuals, NAFLD has been shown to occur in non-obese subjects. This subset of individuals, known to have ‘lean NAFLD’ or ‘non-obese NAFLD’, is also growing increasingly prevalent. We summarize the clinical manifestations, pathophysiology and management of lean NAFLD in both adult and pediatric populations.
The article by Sch önfels et al., “Histological improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score)” adds to our understanding of non-alcoholic fatty liver disease (NAFLD), its relationship to obesity, and the effects of various bariatric procedu res on such obesity-related conditions. In 2005 Kleiner et al. described the NAS , a tool originally intended to quantify changes in NAFLD in patients undergoing therapeutic trials. Strictly speaking, the diagnosis of non-alcoholic steatohepatitis (NASH) is made histologically, in pati...
ConclusionsOur findings support the suggestions that small intestinal length regulates TG metabolism before and after LRYGB. Therefore, modification of the length of bypassed small intestine based on measured total small intestinal length could optimize the outcomes of the elective LRYGB.
Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.
This study suggests that enterohepatic circulation of bile acids might be one of the factors that can affect sex dimorphism in NAFLD development, which underlines the importance of including female models in NAFLD research field. PMID: 30095299 [PubMed - as supplied by publisher]
Publication date: Available online 3 August 2018Source: Food Research InternationalAuthor(s): Maria Eliza de Castro Moreira, Fernnda de Oliveira Araújo, Andressa Rodrigues de Sousa, Renata Celi Lopes Toledo, Laércio dos Anjos Benjamin, Marcia Paranho Veloso, Kassius de Souza Reis, Marcelo Henrique dos Santos, Hercia Stampini Duarte MartinoAbstractThe aim was to evaluate the effect of the ethanol extract of bacupari peel (EEB) on biometric measurements, hepatic lipogenesis and progression of non-alcoholic fatty liver disease (NAFLD) in obese Wistar rats. Chemical analysis of the bacupari peel extract identifie...
ConclusionsThis study highlights the crucial role that lipids play in the independent development of both NAFLD and CKD and demonstrates the importance of lipid-lowering treatments in various metabolic diseases featured by lipid load, from the “rare” GSDIa to the “epidemic” morbid obesity or type 2 diabetes.Graphical abstract